Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 5, 2007

SymBio Obtains Rights to Leukemia Drug Candidate

  • SymBio Pharmaceuticals obtained rights to a drug that’s touted to have therapeutic potential to treat Gleevec-resistant chronic myeloid leukemia and mast cell leukemia.

    PEG-ZnPP was developed by Hiroshi Maeda and fellow researchers at Sojo University. According to Maeda, PEG-ZnPP exhibits an inhibitory antitumor effect on heme oxygenase activity, leading to an increase in the production of toxic oxidants and eventual cancer cell death.

    This exclusive global license adds a third clinical candidation to SymBio’s pipeline.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »